Abstract. The prognosis of patients with human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is poorer than those with HPV-positive HNSCC. The present study aimed to identify novel and specific biomarkers of HPV-negative HNSCC using bioinformatics analysis and associated experiments. The gene expression profiles of HPV-negative HNSCC tissues and corresponding clinical data were downloaded from The Cancer Genome Atlas database and used in a weighted gene co-expression network analysis. Genes in clinically significant co-expression modules were used to construct a protein-protein interaction (PPI) network. The genes demonstrating a high degree score in the PPI network and a high correlation with tumor grade were considered hub genes. The diagnostic value of the hub genes associated with HPV-negative and HPV-positive HNSCC was analyzed using differential expression gene (DEG) analysis, immunohistochemical (IHC) staining and a receiver operating characteristic (ROC) curve analysis. Seven genes [Serrate RNA effector molecule (SRRT), checkpoint kinase 2 (CHEK2), small nuclear ribonucleoprotein polypeptide E (SNRPE), proteasome 26S subunit ATPase 2 (PSMC2), origin recognition complex subunit 5 (ORC5), S100 calcium binding protein A7 and keratinocyte differentiation associated protein (KRTDAP)] were demonstrated to be hub genes in clinically significant co-expression modules. DEG, IHC and ROC curve analyses revealed that SRRT, CHEK2 and SNRPE were significantly upregulated in HPV-negative and HPV-positive HNSCC tissues compared with in adjacent tissues, and these genes demonstrated a high diagnostic value for distinguishing HNSCC tissues. However, PSMC2, ORC5 and KRTDAP were the only differentially expressed genes identified in HPV-negative HNSCC tissues, and these genes demonstrated a high diagnostic value for HPV-negative HNSCC. PSMC2, ORC5 and KRTDAP may therefore serve as novel and specific biomarkers for HPV-negative HNSCC, potentially improving the diagnosis and treatment of patients with HPV-negative HNSCC.

Introduction

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignancy worldwide (1). There are ~650,000 new cases of HNSCC diagnosed every year, with ~350,000 associated deaths occurring in a year (2). Several risk factors involved in the development of HNSCC have been identified, including alcohol, tobacco use and human papillomavirus (HPV) infection, the latter of which is a major independent risk factor for HNSCC (3). Compared with HPV-positive HNSCC, HPV-negative HNSCC is more aggressive and is associated with a higher rate of drug resistance (4). Similarly, patients with HPV-negative HNSCC demonstrate lower overall survival rates than those with HPV-positive HNSCC (5). The identification of novel and specific biomarkers for HPV-negative HNSCC may therefore help to improve the understanding of the mechanism that underlies the progression of HPV-negative HNSCC, as well as to improve the diagnosis and treatment of the disease.

With the progression of high-throughput sequencing technology and bioinformatics methods, additional oncogenes involved in the development of HNSCC have been identified (6,7). Weighted gene co-expression network analysis (WGCNA) is a bioinformatics method that involves calculating the associations between gene co-expression modules and clinical traits using a weighted soft threshold (8). Recently, with the use of WGCNA, a series of biomarkers for HNSCC have been identified. For example, Song et al (9) identified 16 genes involved in the immune and inflammatory response...
that promoted the development of HNSCC. Similarly, using WGCNA, Zhang et al (10) identified 12 genes associated with perineural invasion in patients with HNSCC. However, the molecular mechanism of each HNSCC subtype is different, and the feasibility and specificity of the majority of biomarkers obtained from previous studies are limited.

The current study combined WGCNA, differential expression gene (DEG) analysis and experimental verification to identify specific biomarkers for HPV-negative HNSCC.

Materials and methods

Clinical specimens. A total of 62 pairs of primary HNSCC tissues and adjacent non-tumor tissues (1-2 cm distance from the tumor tissues) were collected from patients at The Affiliated Hospital of Guizhou Medical University (Guiyang, China). None of the enrolled patients underwent treatment (such as chemotherapy or radiation) prior to tissue collection. HPV infection status had been determined prior to study commencement by performing in situ hybridization (ISH), as previously described (11), and P16 staining (Fig. S1). HPV-positive HNSCC was diagnosed based on ISH or P16 (also named p16INK4a) positive results, while HPV-negative HNSCC was defined based on negative ISH and P16 results. A total of 35 patients with HPV-positive HNSCC (26 tissues were ISH and P16 positive, 9 tissues were ISH positive only and none of the tissues were P16 positive only) and 27 patients with HPV-negative HNSCC were enrolled in the present study. The basic clinical characteristics (American Joint Committee on Cancer) (12) of the patients with HPV-negative and HPV-positive HNSCC are presented in Table I. The current study was approved by the Human Trait Ethics Committee of Guizhou Medical University and performed in accordance with the Declaration of Helsinki. All patients who provided samples signed written informed consent.

Data processing. For constructing the WGCNA, the gene expression profiles of 54 HPV-negative HNSCC tissues (ISH and P16 negative stain), along with their corresponding clinical characteristics (Table S1), were downloaded from The Cancer Genome Atlas (TCGA) database (https://portal.gdc.cancer.gov/). After normalization, outliers were assessed using the hierarchical cluster algorithm with a cut-off of 140. A fragments per kilobase of transcript per million mapped reads (FPKM) value of <0.5 was used as the threshold for removing the genes with low expression. This was necessary as a gene must be expressed at a minimal level before it is likely to be translated into a protein or be considered biologically important (13). Consequently, 15,703 genes expressed in the 54 HPV-negative HNSCC tissues, along with the corresponding clinical characteristics data, were used in the WGCNA. For DEGs analysis, the gene expression profile in TCGA and Gene Expression Omnibus datasets [GSE117973 (14), GSE85446 (15) and GSE112026 (16); https://www.ncbi.nlm.nih.gov/gds] containing 103 HPV-positive HNSCC and 165 HPV-negative HNSCC was downloaded. After merge and batch normalization using the sva package (version: 3.11; Bioconductor; https://www.bioconductor.org/packages/release/bioc/html/sva.html), the merge gene expression profile were used for DEGs analysis. ILog fold-change (FC) >0.5 and adjusted P<0.05 were set as cut-off values to consider genes differentially expressed between HPV-positive and HPV-negative HNSCC.

WGCNA. The WGCNA R package (version 1.69; https://cran.r-project.org/web/packages/WGCNA/index.html) was used to conduct the WGCNA. All gene pairs were analyzed using Pearson's correlation analysis, the results of which were used to construct a matrix of similarity. Subsequently, to produce a scale-free co-expression network, the matrix of similarity was constructed using a soft power of β=7. The adjacency matrix was then translated into a topological overlap matrix (TOM). Furthermore, median linkage hierarchical clustering was analyzed using the TOM-based dissimilarity measure with a minimum size of 50.

Identification of clinically significant modules. Following WGCNA, the Pearson's correlation analyses between various module eigengenes and the clinical characteristics of patients were assessed. These traits included node (N) stage, tumor (T) stage, tumor grade, recurrence, perineural invasion, tobacco use history and alcohol consumption history. Modules were considered clinically significant if they were correlated with two clinical characteristics (r>0.3 and P<0.05). In the clinically significant modules, gene significance (GS) was quantified using associations between the individual genes and the clinical characteristics of interest, along with the module membership (MM), which was itself determined using the correlation between the module eigengenes and the gene expression profiles. If P<0.05 for the correlation between GS and MM in the clinically significant modules, the modules were subjected to further analysis.

Construction of a protein-protein interaction (PPI) network. The online Search Tool for the Retrieval of Interacting Genes/Proteins (STRING; http://string-db.org) was used to construct the PPI network. Nodes without connections were removed. The minimum required interaction score was set at 0.7 (high confidence). Node and edge information was exported into a text file, which was subsequently imported into Cytoscape software (version 6.1; https://cytoscape.org/). In the PPI network, nodes represented the protein information encoded by the gene of interest. Lines indicated the interactions between two proteins. The degree score was calculated using the Cytholub plug-in (version 1.0; https://github.com/cytoscape/appstore) and was set as the criterion used to calculate the interaction between a single protein and other proteins. Finally, proteins encoded by genes with a degree score in the top 10% were visualized using Cytoscape, and the genes coding for proteins with a degree score in the top 1% were considered candidate hub genes.

Pearson's correlation analysis between the candidate hub genes and tumor grade. Pearson's correlation analysis between the expression of candidate hub genes and tumor grade was performed using SPSS version 20.0 (IBM Corp.). P<0.05 was set as the cut-off indicating a significant correlation. The genes significantly correlated with tumor grade were considered hub genes.

Immunohistochemical (IHC) staining. All 27 HPV-negative and 35 HPV-positive HNSCC tissues were fixed in
4% paraformaldehyde (Boster Biological Technology) at room temperature. Subsequently, they were embedded into paraffin and cut into 4-µm-thick sections. After heating at 65˚C, the sections were deparaffinized using xylene and rehydrated in a graded ethanol series (100, 80, 60 and 40%). After conducting antigen retrieval using sodium citrate (0.01 mol/l; Boster Biological Technology), endogenous peroxidase activity was blocked using 3% H₂O₂. Subsequently, 5% bovine serum albumin (Wuhan Servicebio Technology Co., Ltd.) was added at room temperature for 1 h. The sections were then incubated for 16 h at 4˚C with the following primary antibodies: p16INK4a (1:200; cat. no. A11651; ABclonal Biotech Co., Ltd.), Serrate RNA effector molecule (SRRT; 1:200; cat. no. A8219; ABclonal Biotech Co., Ltd.), checkpoint kinase 2 (CHEK2; 1:200; cat. no. A19543; ABclonal Biotech Co., Ltd.), small nuclear ribonucleoprotein polypeptide E (SNRPE; 1:200; cat. no. A5488; ABclonal Biotech Co., Ltd.), proteasome 26S subunit ATPase 2 (PSMC2; 1:400; cat. no. 14905‑1‑AP; ProteinTech Group, Inc.), origin recognition complex subunit 5 (ORC5; 1:400; cat. no. 11542‑1‑AP, ProteinTech Group Inc.), S100 calcium binding protein A7 (S100A7; 1:200; cat. no. ab204583; Abcam). Subsequently, the sections were incubated for 2 h at room temperature with anti-mouse (cat. no. A8219; ABclonal Biotech Co., Ltd.), Serrate RNA effector molecule (SRRT; 1:200; cat. no. A19543; ABclonal Biotech Co., Ltd.), checkpoint kinase 2 (CHEK2; 1:200; cat. no. A19543; ABclonal Biotech Co., Ltd.), small nuclear ribonucleoprotein polypeptide E (SNRPE; 1:200; cat. no. A5488; ABclonal Biotech Co., Ltd.), proteasome 26S subunit ATPase 2 (PSMC2; 1:400; cat. no. 14905‑1‑AP; ProteinTech Group, Inc.), origin recognition complex subunit 5 (ORC5; 1:400; cat. no. 11542‑1‑AP, ProteinTech Group Inc.), S100 calcium binding protein A7 (S100A7; 1:200; cat. no. 13061‑1‑AP, ProteinTech Group Inc.) and keratinocyte differentiation associated protein (KRTDAP; 1:1,000; cat. no. ab204583; Abcam). Subsequently, the sections were incubated for 2 h at room temperature with anti-mouse (cat. no. BM3895) and anti-rabbit (cat. no. BM3894) horseradish peroxidase-conjugated goat secondary antibodies (both 1:500; Boster Biological Technology). Samples were then stained with 3,3'-diaminobenzidine and hematoxylin at room temperature for 1 min, after which a light orthophoto microscope (magnification, x200 and x400) was used to obtain images. Finally, the protein expression levels of the target genes were evaluated based on the sum of the intensity score (0, no staining; 1, weakly positive; 2, moderately positive; and 3, strongly positive) and the score for the proportion of positive cells (0, <1; 1, 1‑33; 2, 34‑66; and 3, 67‑100%) using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc.). Total scores of 0-2, 3-4 and 5-6 indicated low, moderate and high expression, respectively. The difference in the protein expression of tissues was determined using Fisher's exact test combined with Bonferroni's correction test based on their expression levels. P<0.05 was considered to indicate a statistically significant difference.

Verification of the diagnostic value of hub genes. The diagnostic value of hub genes for HPV-negative and HPV-positive HNSCC was analyzed using a receiver operating characteristic (ROC) curve analysis using the IHC-based protein levels. The protein expression scores of the HNSCC and normal tissues were imported into SPSS version 20.0 (IBM Corp.), after which ROC curve analysis was performed. An area under the curve (AUC) value of >0.7 was considered to indicate a high diagnostic value.

Results
WGCNA. The gene expression profiles of 54 HPV-negative HNSCC tissues (with negative ISH and P16 staining) were downloaded from the TCGA database, as well as corresponding clinical characteristic data. The sample dendrogram revealed that there were no outliers; similarly, the trait heatmap showed that clinical data of most patients in TCGA database were completely documented (Fig. 1). Therefore, after removing the genes with low expression, the gene expression profiles of all...
SU et al.: PSMC2, ORC5 AND KRTDAP ARE INVOLVED IN HPV-NEGATIVE HNSCC

4 HPV-negative HNSCC tissues were used in the WGCNA. When the soft power \( \beta \) was set as 7, the scale independence of the topology network reached >0.85 (Fig. 2A) with the mean connectivity close to 0 (Fig. 2B). Therefore, a soft power of \( \beta=7 \) was selected as the soft threshold for performing subsequent analyses. The results revealed that when \( \beta=7 \), the topological overlap matrix was able to meet the scale-free topology criterion with \( R^2=0.87 \) (Fig. 2C). The results identified 27 gene co-expression modules (paleturquoise, cyan, salmon, sienna3, violet, royalblue, saddlebrown, darkmagenta, brown, black, purple, lightyellow, darkolivegreen, grey60, yellow, darkgreen, skyblue, lightcyan, lightgreen, tan, darkturquoise, darkorange, blue, green, steelblue, darkgrey and midnightblue), while the genes that were not co-expressed were clustered in the grey module (Fig. 2D). The 27 gene co-expression modules were then used for further analysis.

**Identification of clinically significant modules.** By analyzing the correlation between the gene co-expression modules and clinical characteristics, it was determined that four gene co-expression modules were simultaneously and significantly correlated with two clinical characteristics in patients with HPV-negative HNSCC. The gene of the grey60 module was positively correlated with T stage (\( R=0.38; P=0.004 \)) and tumor grade (\( R=0.32; P=0.03 \)). Genes of the lightyellow module were positively correlated with tumor grade (\( R=0.31; P=0.04 \)) and negatively correlated with perineural invasion (\( R=-0.4; P=0.002 \)). Additionally, genes in the purple module were positively correlated with T stage (\( R=0.32; P=0.02 \)) and tumor grade (\( R=0.31; P=0.03 \)), while genes of the salmon module were negatively correlated with T stage (\( R=-0.31; P=0.02 \)) and tumor stage (\( R=-0.39; P=0.003 \)) (Fig. 3). Correlations between GS and MM were subsequently calculated in the four aforementioned modules. The MM of the grey60 module was correlated with the GS for tumor grade (correlation=0.29; \( P<0.05 \)) and T stage (correlation=0.31; \( P<0.05 \)) (Fig. 4A). The MM of the lightyellow module was correlated with the GS for tumor grade (correlation=0.35; \( P<0.05 \)) and perineural invasion (correlation=0.7; \( P<0.05 \)) (Fig. 4B). The MM of the purple module was correlated with the GS for tumor grade (correlation=0.3; \( P<0.05 \)) and T stage (correlation=0.45; \( P<0.05 \)) (Fig. 4C), while the MM of the salmon module was correlated with the GS for tumor grade (correlation=0.35; \( P<0.05 \)) and T stage (correlation=0.32; \( P<0.05 \)) (Fig. 4D). Therefore, these four modules (grey60, lightyellow, purple and salmon modules) were set as key gene modules and were analyzed further.
Construction of the PPI network and selection of candidate hub genes. The lightyellow, grey60, purple and salmon modules included 201, 997, 2,538 and 389 genes, respectively. After importing these genes into the STRING database and removing the nodes without connections, genes with a degree score in the top 10% in the grey60 (Fig. 5A), lightyellow (Fig. 5B), purple (Fig. 5C) and salmon (Fig. 5D) modules were visualized using Cytoscape. The genes with a degree score in the top 1% in each module are presented in Table II. The resultant 17 genes were considered candidate hub genes and may serve key roles in the development of HPV-negative HNSCC.

Pearson's correlation analysis between the candidate hub genes and tumor grade. As the four gene modules were all correlated with tumor grade, the correlation between candidate hub gene expression and the tumor grade of HPV-negative HNSCC was further analyzed using Pearson's correlation analysis. The results revealed that SRRT (R=0.30; P<0.05), CHEK2 (R=0.29; P<0.05), SNRPE (R=0.31; P<0.05), PSMC2 (R=0.31; P<0.05) and ORC5 (R=0.32; P<0.05) were positively correlated with the tumor grade of HPV-negative HNSCC tissue, while S100A7 (R=-0.38; P<0.05) and KRTDAP (R=-0.29; P<0.05) were negatively correlated with tumor grade (Fig. 6). Therefore, SRRT, CHEK2, SNRPE, PSMC2, ORC5, S100A7 and KRTDAP were identified as hub genes in HPV-negative HNSCC.

Identification of the expression levels of hub genes in HPV-negative and HPV-positive HNSCC. To analyze the expression levels of hub genes in HPV-negative and HPV-positive HNSCC, the merged gene data expression profile of 103 HPV-positive HNSCC and 165 HPV-negative HNSCC samples in TCGA and GEO databases (GSE117973, GSE85446 and GSE112026) was used to perform DEGs analysis. The results revealed that there were 27 upregulated genes and 25 downregulated genes in HPV-negative HNSCC compared with in HPV-positive HNSCC (Fig. 7A; Table III). Through an intersection analysis, it was found that the hub genes ORC5 and PSMC2 were upregulated in HPV-negative HNSCC tissues compared with in HPV-positive HNSCC tissues, while KRTDAP was downregulated (Fig. 7B).

Verification of the protein expression levels of hub genes in HPV-negative and HPV-positive HNSCC tissues. To verify the bioinformatics results, IHC staining of 27 HPV-negative and 35 HPV-positive HNSCC tissues was performed, alongside their corresponding adjacent tissues. The results revealed that the protein expression levels of SRRT, CHEK2 and SNRPE were increased in HPV-negative HNSCC and HPV-positive HNSCC tissues compared with in their adjacent counterparts; however, there was no significant difference between HPV-negative and HPV-positive HNSCC tissues. S100A7 expression was not significantly different among...
SU et al.: PSMC2, ORC5 AND KRTDAP ARE INVOLVED IN HPV-NEGATIVE HNSCC

HPV-negative HNSCC, HPV-positive HNSCC and adjacent tissues. Furthermore, it was demonstrated that PSMC2 and ORC5 expression was significantly increased, while KRTDAP expression was significantly decreased in HPV-negative HNSCC tissues compared with in adjacent and HPV-positive HNSCC tissues (Table IV; Figs. 8 and S2).

Verification of the diagnostic value of hub genes for HPV-negative and HPV-positive HNSCC. Using protein level data obtained by IHC staining, ROC curve analysis was performed. The results revealed that SRRT, CHEK2, SNRPE, PSMC2, ORC5 and KRTDAP exhibited high diagnostic value for distinguishing between HPV-negative HNSCC and adjacent tissues, while S100A7 did not exert this effect (Fig. 9A). However, only SRRT, CHEK2 and SNRPE had high diagnostic value for distinguishing between HPV-positive HNSCC and adjacent tissues (Fig. 9B). Thus, SRRT, CHEK2 and SNRPE may be used as common biomarkers for both HPV-negative and HPV-positive HNSCC, while PSMC2, ORC5 and KRTDAP may be specific biomarkers for HPV-negative HNSCC only.

Figure 3. Identification of clinically significant modules based on the correlation of module eigengenes with clinical characteristics. Each cell contains the corresponding correlation coefficient and P-value (in brackets). The colors indicate the strength of correlation according to the color legend. ME, module; T, tumor; N, node.
Discussion

There are numerous risk factors involved in the pathogenesis of HNSCC, including HPV infection. Although the majority of HNSCC cases involve HPV infection, certain patients develop HNSCC without it (17,18). The molecular mechanisms underlying these two subtypes are different (19). Furthermore, HPV-negative HNSCC is more aggressive than HPV-positive HNSCC (20,21). Therefore, the identification of novel and specific biomarkers for HPV-negative HNSCC may improve the understanding of the specific molecular mechanism associated with HPV-negative HNSCC, which may improve the diagnosis and treatment of patients.

The current study identified four gene co-expression modules associated with clinical characteristics of patients via WGCNA. The results revealed 17 genes in these gene co-expression modules that had a high degree score (top 1% of genes in each module) in the PPI network. Additionally, seven of these genes (SRRT, CHEK2, SNRPE, PSMC2, ORC5, S100A7 and KRTDAP) were correlated with tumor grade in HPV-negative HNSCC. DEG analysis demonstrated that PSMC2 and ORC5 expression was higher in HPV-negative HNSCC compared with in HPV-positive HNSCC, while KRTDAP expression was lower. Furthermore, using IHC staining and ROC curve analysis, it was revealed that SRRT, CHEK2, SNRPE, PSMC2, ORC5 and KRTDAP were differentially expressed in HPV-negative HNSCC tissues compared with in adjacent tissues and had high diagnostic values for distinguishing between HPV-negative HNSCC tissues and adjacent tissues. However, after performing additional IHC staining and ROC curve analysis, it was demonstrated that SRRT, CHEK2 and SNRPE were differentially expressed in HPV-positive HNSCC tissues compared with in adjacent tissues, exhibiting a high diagnostic value for distinguishing between HPV-positive HNSCC and adjacent tissues. Thus, while SRRT, CHEK2 and SNRPE may be used as common

![Figure 4. Analysis of GS and MM in the clinically significant modules. (A) MM of the grey60 module was correlated with GS for tumor grade and T stage. (B) MM in the lightyellow module was correlated with GS for tumor grade and perineural invasion. (C) MM of the purple module was correlated with GS for tumor grade and T stage. (D) MM of the salmon module was correlated with GS for tumor grade and T stage. GS, gene significance; MM, module membership; cor, correlation; T, tumor; N, node.]
biomarkers for both HPV-negative and HPV-positive HNSCC, PSMC2, ORC5 and KRTDAP may be specific to HPV-negative HNSCC only.

SRRT (also named Ars2) was first isolated from a hamster cell line and serves a key role in sodium arsenite resistance (22). Furthermore, it has been demonstrated that SRRT is involved in the biosynthesis of certain microRNAs (23). However, research on the role of SRRT in the development of cancer is conflicting. It has been demonstrated that SRRT serves as an oncogene in glioblastoma and promotes the proliferation and migration of LN-229 and U87 glioblastoma cells via the MAPK/ERK signaling pathway (24). Additionally, SRRT expression is upregulated in cholangiocarcinoma and associated with poor outcomes (25). However, pediatric acute lymphoblastic leukemia involving low SRRT expression has poor chemotherapy outcomes (26). CHEK2 was first reported as an important breast cancer susceptibility gene; it serves a key role in regulating cell apoptosis, cell cycle and DNA repair (27). It increases the stability of P53 and induces cell cycle arrest in the G1 phase (28). However, CHEK2 mutations...
are very common in several types of cancer, including breast cancer (29), colorectal cancer (30) and oral squamous cell carcinoma (31). Additionally, CHEK2 promotes the progression of various types of cancer, including hepatocellular carcinoma (32) and colorectal cancer (33). SNRPE is a member of a large family of polypeptides that are conserved in eukaryotes and archaeabacteria (34). Previous studies have revealed that it is involved in RNA processing and mRNA degradation (35,36). Furthermore, a previous study has revealed that SNRPE is highly expressed in high-grade prostate cancer, promoting cell proliferation (37). In the present study, it was demonstrated that SRRT, CHEK2 and SNRPE were clinically significant gene modules, had high degree scores in the PPI network, were associated with tumor grade and were highly expressed in HPV-negative and HPV-positive HNSCC tissues. Furthermore, it was revealed that SRRT, CHEK2 and SNRPE had a high diagnostic value in distinguishing HNSCC and adjacent tissues. Therefore, to the best of our knowledge, the present study was the first to demonstrate that SRRT, CHEK2, and SNRPE may be used as common biomarkers for both HPV-negative and HPV-positive HNSCC. Targeting SRRT, CHEK2 and SNRPE may aid in the therapy of patients with HPV-negative and HPV-positive HNSCC. However, the mechanism of SRRT, CHEK2 and SNRPE in the development of HNSCC requires further study.

PSMC2 is a novel gene on chromosome 7q22.1-q22.3 that encodes a member of the 19S proteasome (38). Recently, PSMC2 was revealed as an oncogene in several types of cancer.

**Table II. Genes with a degree score in the top 1% in each module.**

| Module          | Gene     | Degree score |
|-----------------|----------|--------------|
| Grey60 module   | SNRPG    | 20           |
|                 | SNRPF    | 18           |
|                 | SNRPE    | 16           |
|                 | SNRPD1   | 16           |
|                 | NOP58    | 16           |
| Salmon module   | S100A7   | 8            |
|                 | KRTDAP   | 7            |
| Purple module   | DDX39B   | 5            |
|                 | CHEK2    | 4            |
|                 | KAT2A    | 4            |
| Lightyellow module | ORC5    | 4            |
|                 | PSMC2    | 4            |
|                 | SRRT     | 4            |
|                 | BUD31    | 4            |
|                 | POLR2J   | 4            |
|                 | ARMC10   | 4            |
|                 | RBM48    | 4            |

SRRT, serrate RNA effector molecule; CHEK2, checkpoint kinase 2; SNRPE, small nuclear ribonucleoprotein polypeptide E; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; S100A7, S100 calcium binding protein A7; KRTDAP, keratinocyte differentiation associated protein.

### Table III. Detailed information of genes differently expressed in HPV-negative and HPV-positive head and neck squamous cell carcinoma according to the different expression analysis.

| Gene   | Log (fold-change) |
|--------|-------------------|
| DSG1   | 0.814689016       |
| SPRR2G | 0.807843405       |
| KLK5   | 0.78303004        |
| KRT1   | 0.735022158       |
| PSMC2  | 0.729090901       |
| MMP10  | 0.701782465       |
| ORC5   | 0.655262803       |
| SPRR2B | 0.650839232       |
| LCE3E  | 0.646742549       |
| DSC1   | 0.622678244       |
| KLK7   | 0.622536747       |
| DEFB103B| 0.602302594     |
| PTHLH  | 0.598659999       |
| MMP13  | 0.588604647       |
| MMP3   | 0.584023444       |
| FAM25A | 0.576520859       |
| ASPRV1 | 0.566257594       |
| LCE3D  | 0.564179626       |
| CCNA1  | 0.561757208       |
| KLK8   | 0.558113758       |
| CPA4   | 0.555893249       |
| IGFL1  | 0.551152103       |
| CDSN   | 0.532580373       |
| KRT75  | 0.521895677       |
| CDA    | 0.512697702       |
| PSMC2  | 0.506358839       |
| MEI1   | 0.506787682       |
| CYP4X1 | -0.506787682      |
| SYNGR3 | -0.514548202      |
| RIBC2  | -0.514701295      |
| RNF212 | -0.517145557      |
| ABCA3  | -0.528340922      |
| TMPRSS2| -0.530093548      |
| TMSB15A| -0.532159011      |
| KRTDAP | -0.548534666      |
| MEI1   | -0.551064139      |
| GABRP  | -0.554796624      |
| CDKN2C | -0.560982919      |
| YBX2   | -0.569455778      |
| TCP11  | -0.570473276      |
| KRT19  | -0.578420257      |
| SMC1B  | -0.580791027      |
| PODXL2 | -0.59651466       |
| FABM3  | -0.603548652      |
| STAG3  | -0.606559892      |
| TAF7L  | -0.627355888      |
| ZNF541 | -0.677964463      |
| KCNS1  | -0.683806065      |
| SYCP2  | -0.735795983      |
| NEFH   | -0.757761211      |
| CDKN2A | -0.768176467      |

HPV, human papillomavirus; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; KRTDAP, keratinocyte differentiation associated protein.
cancer, including pancreatic cancer (39) and osteosarcoma (40). Similarly, high PSMC2 expression predicts a poor prognosis in patients with osteosarcoma (41). ORC5 is a key member of the origin recognition complex that...
binds to replication origins, initiating replication itself (42). Additionally, it induces large-scale chromatin decondensation and regulates the cell cycle and proliferation (43). KRTDAP acts as a soluble regulator of keratinocyte differentiation and serves a key role in embryonic skin morphogenesis (44). Research has revealed that KRTDAP mRNA is upregulated in HPV-positive HNSCC tissues compared with adjacent tissues (45). In the present study, it was demonstrated that PSMC2 and ORC5 expression was significantly increased in HPV-negative HNSCC tissues compared with adjacent tissues. Additionally, KRTDAP was significantly decreased in HPV-negative HNSCC tissues compared with adjacent tissues. Similarly, it was revealed that PSMC2, ORC5 and KRTDAP had a high diagnostic value in distinguishing HPV-negative HNSCC and adjacent tissues. However, it could not distinguish between HPV-positive HNSCC and adjacent tissues. Therefore, it was hypothesized that PSMC2, ORC5 and KRTDAP may be used as specific biomarkers for HPV-negative HNSCC only. It is well known that HPV-negative HNSCC cells are more aggressive than HPV-positive HNSCC cells. Therefore, the downregulation of KRTDAP and upregulation of PSMC2 and ORC5 may be key for HPV-negative HNSCC cells to become aggressive. Targeting ORC5, PSMC and KRTDAP may therefore help the individualized treatment of patients with HPV-negative HNSCC. However, additional experiments should be performed to verify this hypothesis.

In conclusion, based on WGCNA, PPI network, Pearson's correlation, DEG, IHC and ROC curve analyses, SRRT, CHEK2 and SNRPE were revealed to be common biomarkers for both HPV-negative and HPV-positive HNSCC, while PSMC2, ORC5 and KRTDAP may be potential specific biomarkers for HPV-negative HNSCC. SRRT, serrate RNA effector molecule; CHEK2, checkpoint kinase 2; SNRPE, small nuclear ribonucleoprotein polypeptide E; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; S100A7, S100 calcium binding protein A7; KRTDAP, keratinocyte differentiation associated protein; HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma.

Table IV. Detailed immunohistochemical scoring of SRRT, CHEK2, SNRPE, PSMC2, ORC5, S100A7 and KRTDAP expression in HPV+ HNSCC (n=27), HPV− HNSCC (n=35) and corresponding adjacent tissues.

| Gene   | Tissues          | Low expression (0-2), n | Medium expression (3-4), n | High expression (5-6), n |
|--------|------------------|-------------------------|----------------------------|--------------------------|
| SRRT   | Tumor (HPV+) b,c | 5                       | 4                          | 26                       |
|        | Adjacent (HPV+)  | 27                      | 6                          | 2                        |
|        | Tumor (HPV−)     | 2                       | 3                          | 22                       |
|        | Adjacent (HPV−)  | 18                      | 6                          | 3                        |
| CHEK2  | Tumor (HPV+) b,c | 3                       | 3                          | 29                       |
|        | Adjacent (HPV+)  | 28                      | 4                          | 3                        |
|        | Tumor (HPV−)     | 5                       | 4                          | 18                       |
|        | Adjacent (HPV−)  | 18                      | 7                          | 2                        |
| PSMC2  | Tumor (HPV+)     | 15                      | 13                         | 7                        |
|        | Adjacent (HPV+)  | 22                      | 7                          | 6                        |
|        | Tumor (HPV−) b,c | 2                       | 3                          | 22                       |
|        | Adjacent (HPV−)  | 20                      | 5                          | 2                        |
| OCR5   | Tumor (HPV+)     | 19                      | 10                         | 6                        |
|        | Adjacent (HPV+)  | 24                      | 9                          | 2                        |
|        | Tumor (HPV−) b,c | 2                       | 7                          | 18                       |
|        | Adjacent (HPV−)  | 19                      | 5                          | 3                        |
| S100A7 | Tumor (HPV+)     | 6                       | 5                          | 24                       |
|        | Adjacent (HPV+)  | 4                       | 4                          | 27                       |
|        | Tumor (HPV+)     | 2                       | 4                          | 21                       |
|        | Adjacent (HPV+)  | 4                       | 5                          | 18                       |
| SNRPE  | Tumor (HPV+)     | 3                       | 4                          | 28                       |
|        | Adjacent (HPV+)  | 26                      | 3                          | 6                        |
|        | Tumor (HPV−)     | 4                       | 2                          | 21                       |
|        | Adjacent (HPV−)  | 17                      | 6                          | 4                        |
| KRTDAP | Tumor (HPV+)     | 9                       | 6                          | 20                       |
|        | Adjacent (HPV+)  | 8                       | 8                          | 19                       |
|        | Tumor (HPV−) b,c | 20                      | 4                          | 3                        |
|        | Adjacent (HPV−)  | 4                       | 7                          | 16                       |

P<0.05 vs. HPV+ adjacent tissues; P<0.05 vs. HPV− adjacent tissues; P<0.05 vs. HPV+ HNSCC. SRRT, serrate RNA effector molecule; CHEK2, checkpoint kinase 2; SNRPE, small nuclear ribonucleoprotein polypeptide E; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; S100A7, S100 calcium binding protein A7; KRTDAP, keratinocyte differentiation associated protein; HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma.
Figure 8. Immunohistochemistry was used to detect the protein expression levels of SRRT, CHEK2, SNRPE, PSMC2, ORC5, S100A7 and KRTDAP in HPV-negative HNSCC, HPV-positive HNSCC and adjacent tissues (magnification, x200 and x400). Black scale bar, 100 µm; white scale bar, 50 µm. SRRT, serrate RNA effector molecule; CHEK2, checkpoint kinase 2; SNRPE, small nuclear ribonucleoprotein polypeptide E; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; S100A7, S100 calcium binding protein A7; KRTDAP, keratinocyte differentiation associated protein; HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; N, normal tissues; T, tumor tissues.

Figure 9. Receiver operating characteristic curve analysis was used to determine the diagnostic value of SRRT, CHEK2, SNRPE, PSMC2, ORC5, S100A7 and KRTDAP for (A) HPV-negative and (B) HPV-positive HNSCC based on protein level data obtained by immunohistochemical staining. AUC >0.7 indicated genes with high diagnostic value for distinguishing between HNSCC and adjacent tissues. SRRT, serrate RNA effector molecule; CHEK2, checkpoint kinase 2; SNRPE, small nuclear ribonucleoprotein polypeptide E; PSMC2, proteasome 26S subunit ATPase 2; ORC5, origin recognition complex subunit 5; S100A7, S100 calcium binding protein A7; KRTDAP, keratinocyte differentiation associated protein; HPV, human papillomavirus; HNSCC, head and neck squamous cell carcinoma; AUC, area under the curve.
HPV-negative HNSCC. The results may improve the understanding of HNSCC, as well as providing potential biomarkers and targets for the diagnosis and treatment of patients with this disease.

Acknowledgements

Not applicable.

Funding

The current study was supported by Guizhou Big Data Health Management Industry Technology Innovation Strategic Alliance [grant no. Qianketong (2016)193].

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request, and the GSE117973, GSE85446 and GSE112026 datasets analyzed during the current study are available in the Gene Expression Omnibus repository (https://www.ncbi.nlm.nih.gov/geo/).

Authors' contributions

YS, YC and ZZ were responsible for the experimental design, analysis and interpretation of data. DR, YY and BW performed the experiments. YS and YC were responsible for confirming the authenticity of the data. All authors took part in drafting the article and revising it critically for important intellectual content, agreed to be accountable for all aspects of the work, and read and approved the final manuscript.

Ethics approval and consent to participate

The current study was approved by the Human Trait Ethics Committee of Guizhou Medical University (Guiyang, China) and performed in accordance with the Declaration of Helsinki. All patients from which samples were obtained provided written informed consent.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6: 92, 2020.
2. Dhall AK, Atri R, Dhankhar R, Chauhan AK and Kaushal V: Major risk factors in head and neck cancer: A retrospective analysis of 12-year experiences. World J Oncol 9: 80-84, 2018.
3. Płazik J, Bouček J, Bandúrová V, Kolář M, Hradilová M, Szabo P, Lacina L, Chovanec M and Smetana K Jr: The head and neck squamous cell carcinoma microenvironment as a potential target for cancer therapy. Cancers (Basel) 11: 440, 2019.
4. Sabatini ME and Chiocca S: Human papillomavirus as a driver of head and neck cancers. Br J Cancer 122: 306-314, 2020.
5. Viros Porcuna D, Pollan Guisasola C, Viña Soria C, Cirauqui B, Parado Muñoz L, Collurá F and Mestia Nin R: Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population. Clin Transl Oncol 22: 1303-1311, 2020.
6. Shen Y, Liu J, Zhang L, Dong S, Zhang J, Liu Y, Zhou H and Dong W: Identification of potential biomarkers and survival analysis for head and neck squamous cell carcinoma using biominformatics strategy: A study based on TCGA and GEO datasets. Biomed Res Int 2019: 7376034, 2019.
7. Yang B, Fu L, Xu S, Xiao J, Li Z and Liu Y: A nomogram based on a gene signature for predicting the prognosis of patients with head and neck squamous cell carcinoma. Int J Biol Markers 34: 309-317, 2019.
8. Langfelder P and Horvath S: WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics 9: 559, 2008.
9. Song Y, Fan Y and Liu J: The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma. Cancer Manag Res 11: 7455-7472, 2019.
10. Zhang Z, Liu R, Jin R, Fan Y, Li T, Shuai Y, Li X, Wang X and Luo J: Integrating clinical and genetic analysis of perineural invasion in head and neck squamous cell carcinoma. Front Oncol 9: 434, 2019.
11. Chi J, Preeshagul IR, Sheikh-Fayyaz S, Teckie S, Kohn N, Ziemia Y, Laser A, Frank D, Ghaly M, Kamdar D, et al.: Evaluating of HPV-DNA ISH as an adjunct to p16 testing in oropharyngeal cancer. Future Sci OA 6: FSO606, 2020.
12. Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head and neck cancers-major changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67: 122-137, 2017.
13. Bi N, Sun Y, Lei S, Zeng Z, Zhang Y, Sun C and Yu C: Identification of 40S ribosomal protein S8 as a novel biomarker for alcohol-associated hepatocellular carcinoma using weighted gene co-expression network analysis. Oncol Rep 44: 611-627, 2020.
14. Feng B, Shen Y, Pastor Hostench X, Bieg M, Platth M, Ishaque N, Eils R, Freier K, Weichert W, Zaoui K and Hess J: Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer. Clin Cancer Res 26: 3616-3628, 2020.
15. Mes SW, Te Beesti D, Poli T, Rossi S, Scheckenbach K, van Wieringen WN, Brink A, Bertani N, Lanfranco D, Silini EM, et al.: Prognostic modeling of oral cancer by gene profiles and clinicopathological co-variables. Oncotarget 8: 93912-93923, 2017.
16. Kelsky DZ, Flam EL, Izumchenko E, Danilova LV, Wulf HA, Guo T, Singman DA, Adsari B, Skaist AM, Considine M, et al.: Integrated analysis of whole-genome ChIP-Seq and RNA-Seq data of primary head and neck tumor samples associates HPV integration sites with open chromatin marks. Cancer Res 77: 6538-6550, 2017.
17. Jethwa AR and Khariwala SS: Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev 38: 411-423, 2017.
18. Paver EC, Currie AM, Gupta R and Dahlstrom JE: Human papillomavirus related squamous cell carcinomas of the head and neck: Diagnosis, clinical implications and detection of HPV. Pathology 52: 179-191, 2020.
19. Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozeck LS and Sartor MA: HPV Integration in HNSCC correlates with survival outcomes, immune response signatures, and candidate drivers. Mol Cancer Res 16: 90-102, 2018.
20. Qian X, Nguyen DT, Dong Y, Sinikovic B, Kaufmann AM, Myers JN, Ålbers AE and Graviss EA: Prognostic score predicts survival in HPV-negative head and neck squamous cell cancer patients. Int J Biol Sci 15: 1336-1344, 2019.
21. Vossen DM, Verhagen JVM, van der Heijden M, Essers PBM, Bartelink H, Verheij M, Wessels LFA, van den Brekel MWM and Vossen DM, Verhagen CVM, van der Heijden M, Essers PBM, Bartelink H, Verheij M, Wessels LFA, van den Brekel MWM and Vanselow MA: Identification of 40S ribosomal protein S8 as a novel biomarker for alcohol-associated hepatocellular carcinoma using weighted gene co-expression network analysis. Oncol Rep 44: 611-627, 2020.
22. Elahi S, Egan SM, Holling GA, Kandefer RL, Nemeth MJ and Olejniczak SH: The RNA binding protein Ars2 supports hematopoiesis at multiple levels. Exp Hematol 46: 45-58.e9, 2018.
23. Gruber JJ, Olejniczak SH, Yong J, La Rocca G, Dreyfuss G and Thompson CB: Ars2 promotes proper replication-dependent histone mRNA 3' end formation. Mol Cell 45: 87-98, 2012.

24. Ke X, Pang Y, Chen K, Zhang D, Wang F, Zhu S, Mao J, Hu X, Zhang G and Cui H: Knockdown of arsenic resistance protein 2 inhibits human glioblastoma cell proliferation through the MAPK/ERK pathway. Oncol Rep 40: 3313-3322, 2018.

25. He Q, Cai L, Shuai L, Li D, Wang C, Liu Y, Li X, Li Z and Wang S: Ars2 is overexpressed in human cholangiocarcinomas and its depletion increases PTEN and PDCD4 by decreasing microRNA-21. Mol Carcinog 52: 286-296, 2013.

26. Cui L, Gao C, Zhang RD, Jiao Y, Li WJ, Zhao XX, Liu SG, Yue ZX, Zheng HY, Deng GR, et al: Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol. Leuk Res 39: 115-123, 2015.

27. Ansari N, Shahraibi S, Khozarski A, Shrizad R and Rezaeean H: Prognostic significance of CHEK2 mutation in progression of breast cancer. Lab Med 50: e36-e41, 2019.

28. Luo Q, Guo H, Kuang P, Cui H, Deng H, Liu H, Lu Y, Wei Q, Chen L, Fang J, et al: Sodium fluoride arrests renal G2/M phase cell-cycle progression by activating ATM-Chk2-P53/Cdc25C signaling pathway in mice. Cell Physiol Biochem 51: 2421-2433, 2018.

29. Apostolopou L and Papasotiropou I: Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press) 9: 331-335, 2017.

30. Wang W, Guo M, Xia X, Zhang C, Zeng Y and Wu S: XRR1 targets ATM/CHK1/2-mediated DNA repair in colorectal cancer. Biomed Res Int 2017: 5718968, 2017.

31. Yoon AJ, Shen J, Santetia RM, Zegarelli DJ, Chen R and Weinstein IB: Activated checkpoint kinase 2 inhibits human glioblastoma cell proliferation and inhibits apoptosis. J Cancer 10: 4939-4946, 2019.

32. Li GW and Yan X: Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2. Eur Rev Med Pharmacol Sci 23: 1915-1925, 2019.

33. Shibata E and Dutta A: A human cancer cell line initiates DNA replication normally in the absence of ORC5 and ORC2 proteins. J Biol Chem 295: 16949-16959, 2020.

34. Giri S, Chakraborty A, Sathyan KM, Prasanth KV and Prasanth SG: Orc5 induces large-scale chromatin decondensation in a GCN5-dependent manner. J Cell Sci 129: 417-429, 2016.

35. Oomizu S, Sahuc F, Asahina K, Inamatsu M, Matsuza K, Sasaki M, Obara M and Yoshizato K: Kdap, a novel gene associated with the stratification of the epithelium. Gene 256: 19-27, 2000.

36. Chen T, Zhang B, Ziegenhals T, Prusty AB, Fröhler S, Grimm C, Hu Y, Schaeveke B, Fang L, Zhang M, et al: A missense mutation in SNRPE linked to non-syndromal microcephaly interferes with U snRNP assembly and pre-mRNA splicing. PLoS Genet 15: e1008460, 2019.

37. Anchi T, Tamura K, Furihata M, Satakate H, Sakada H, Kawada C, Kamei M, Shimamoto T, Fukuhara H, Fukuta S, et al: SNRPE is involved in cell proliferation and progression of high-grade prostate cancer through the regulation of androgen receptor expression. Oncol Lett 3: 264-268, 2012.

38. Je H, Xing J, Yang X, Zhang C, Zhang Y, Wang H, Xu X, Wang H, Cao Y, Xu H, et al: Silencing of proteasome 26S subunit ATPase 2 regulates colorectal cancer cell proliferation, apoptosis, and migration. Chemotherapy 64: 146-154, 2018.

39. Qin J, Wang W, An F, Huang W and Ding J: PSMC2 is up-regulated in pancreatic cancer and promotes cancer cell proliferation and inhibits apoptosis. J Cancer 10: 4939-4946, 2019.

40. Song M, Wang Y, Zhang Z and Wang S: PSMC2 is up-regulated in osteosarcoma and regulates osteosarcoma cell proliferation, apoptosis and migration. Oncotarget 8: 933-953, 2017.

41. Li GW and Yan X: Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2. Eur Rev Med Pharmacol Sci 23: 1915-1925, 2019.